Published on
May 18, 2026
- 10:30 GMT
TriCelX Files FDA IND for XytriX™ in Chronic Traumatic Encephalopathy (CTE)
XytriX™ Becomes First CTE Biotherapeutic to Reach FDA Under the Blast Overpressure Safety Act FRISCO, TX, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- TriCelX, Inc. (“TriCelX”), a translational leader in evidence-based biotherapeutics, has …
Distribution channels:
Business & Economy, Healthcare & Pharmaceuticals Industry
...
